Penumbra, Inc.

Valuation Analysis

About the Company

Penumbra, Inc. en bref

Penumbra, Inc. (PEN) is currently trading at 276,40 € with a market capitalization of 10,9 Md €. The trailing P/E ratio stands at 73.22x, with a forward P/E of 50.47x. The 52-week range spans from 192,89 € to 315,94 €; the current price is 12.5% below the yearly high. Year-over-year revenue growth stands at +15.6%. The net profit margin stands at 11.76%.

💰 Dividende

Penumbra, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

14 analystes évaluent Penumbra, Inc. (PEN) au consensus : Conserver. L'objectif de cours moyen est de 316,76 €, soit un potentiel de +14.6% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 284,20 € à 326,04 €.

Penumbra, Inc. : la thèse d'investissement en détail

Penumbra, Inc. (PEN) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 15.6% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 67.38%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

Le scénario baissier

A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

With a PEG ratio of 0.73, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 59.45x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The forward P/E of 50.47x is meaningfully below the trailing 73.22x — analysts expect earnings to step up; the next earnings release is the test.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (5.6%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Penumbra, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.